Today: 21 May 2026
D-Wave stock steadies after brutal pullback as Wall Street targets clash
29 December 2025
2 mins read

D-Wave stock steadies after brutal pullback as Wall Street targets clash

NEW YORK, December 29, 2025, 10:07 ET

  • D-Wave Quantum shares were little changed on Monday after a three-session slide that erased most of a Dec. 22 surge.
  • Analyst price targets for the quantum-computing company range from the mid-$30s to mid-$40s, while some bearish notes flag deeper downside.
  • Quantum peers IonQ, Rigetti and Quantum Computing Inc were lower in early trading.

D-Wave Quantum shares were little changed on Monday as the stock tried to stabilize after a sharp pullback that has renewed debate over how to value early-stage quantum-computing companies. Shares traded at about $25.35 in morning trade.

The swings matter because U.S.-listed “pure-play” quantum stocks — companies focused mainly on quantum rather than diversified technology businesses — have become one of the market’s most volatile corners into year-end. New analyst coverage has added targets and narratives, but it has not narrowed the gap between bullish long-term forecasts and near-term valuation concerns. Fintel+3TipRanks+3TipRanks+3

D-Wave is also headed into January with a set of high-visibility events that traders have treated as sentiment catalysts, including appearances tied to CES 2026 and the company’s annual user conference.

Price data from show D-Wave jumped 20% on Dec. 22 to close at $32.19, then fell in each of the next three sessions to end Dec. 26 at $25.29. Friday’s trading range ran from $24.765 to $27.50, with 33.56 million shares traded, the same data showed.

A weekend round-up by said the retreat followed a headline-fueled surge and quick profit-taking, with no major company-specific negative news cited.

The Dec. 22 jump came after D-Wave said it would participate in CES 2026 as a sponsor of the CES Foundry, a two-day event in Las Vegas on Jan. 7-8. “The technology is quickly moving into the mainstream,” said Murray Thom, vice president of quantum technology evangelism, in the company’s CES announcement. D-Wave Quantum

D-Wave sells quantum systems and cloud access, and it is best known for “quantum annealing” — a quantum approach used mainly for optimization problems such as scheduling and routing — alongside longer-term work on “gate-model” systems that aim to run more general quantum algorithms. D-Wave Quantum+1

The valuation debate has been sharpened by the company’s small revenue base. In its third-quarter results released in November, D-Wave said revenue was $3.7 million and it held more than $836 million in cash as of Sept. 30.

Wall Street’s target spread reflects how uneven expectations remain. Wedbush initiated coverage with an Outperform rating and a $35 price target, while Jefferies started with a Buy and a $45 target and Mizuho with an Outperform and a $46 target, according to separate posts from TheFly on , and .

On a broader consensus view, data on showed an average one-year price target of $38.59, with forecasts ranging from $22.77 to $50.40.

Bearish notes have pushed back on the rally. In a Dec. 27 analysis, Trefis said $18 “is not out of question,” citing past trading levels and its negative view on the stock. Trefis

The wider quantum group also slipped on Monday. IonQ shares were down about 1.8% at $45.19, Rigetti fell about 3.1% to $21.69, and Quantum Computing Inc dropped about 2.2% to $10.43.

The recent move in D-Wave stands out even within a sector known for sharp swings. Investing.com listed D-Wave’s 52-week range at $3.74 to $46.75.

A highlighted D-Wave’s commercial positioning and cash balance, but said a much bigger re-rating would likely require progress toward fault-tolerant — meaning error-corrected — gate-model systems.

Quantum stocks have drawn attention beyond Wall Street research, with noting last week that the group has swung sharply during holiday trading.

For D-Wave investors, the next test is whether January’s CES and conference appearances can sustain momentum after the pullback — or whether valuation concerns continue to dominate trading into the new year.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Microsoft stock dips as Wall Street’s year-end rally pauses, Fed minutes loom
Previous Story

Microsoft stock dips as Wall Street’s year-end rally pauses, Fed minutes loom

New expressway makes Ahmedabad-to-Salangpur Hanuman temple trip faster — even before official opening
Next Story

New expressway makes Ahmedabad-to-Salangpur Hanuman temple trip faster — even before official opening

Go toTop